SCHEMBL680275

SCHEMBL680275

CS(=O)(=O)NC(=O)c1ccc(Cc2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 9/20 0.68
HAO1 Q9UJM8 1/20 0.55
PTPRG P23470 2/20 0.54
PTPRC P08575 1/20 0.52
CCR2 P41597 1/20 0.51
HDAC4 P56524 1/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC7 Q8WUI4 1/20 0.48
HDAC11 Q96DB2 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HDAC9 Q9UKV0 1/20 0.48
HDAC5 Q9UQL6 1/20 0.48
SLC6A2 P23975 2/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
GRIN1 Q05586 1/20 0.46
GRIN2B Q13224 1/20 0.46
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10203178 0.83 SCN9A (0.66) SCN9APTPRGSCN5A
SCHEMBL680292 0.81 SCN9A (0.65) SCN9APTPRGSLC6A2SLC6A4SLC6A3
SCHEMBL16240196 0.80 SCN9A (0.77) SCN9ASCN5A
SCHEMBL680556 0.77 SCN9A (0.68) SCN9ASCN5ATSHR
SCHEMBL678860 0.77 SCN9A (0.68) SCN9APTPRGPTPRCCCR2FLT1
SCHEMBL11224189 0.77 KMT2A (0.68) HAO1SLC6A2SLC6A4SLC6A3TSHR
SCHEMBL17946838 0.75 SCN9A (0.78) SCN9ASCN5A
SCHEMBL7973340 0.75 PLK1 (0.61) SCN9ATSHRPTPN1
SCHEMBL366289 0.75 HAO1 (0.67) HAO1SLC6A2SLC6A4SLC6A3TSHR
SCHEMBL7990845 0.74 FLT1 (0.65) SCN9AFLT1FLT4KDRSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US claimed
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SCN9A 13/4885HAO1 2919/4885PTPRG 2135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.